LR 19024
Alternative Names: LR-19024Latest Information Update: 06 Jun 2024
At a glance
- Originator LG Chem
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Osteoarthritis
Most Recent Events
- 16 Apr 2024 LR 19024 is available for licensing as of 16 Apr 2024. https://innovation.lgchem.com/ResearchDevelopment/Partnership.do
- 16 Apr 2024 Phase-II clinical trials in Osteoarthritis in South Korea (unspecified route), before April 2024 (LG Chem pipeline, April 2024)
- 30 Jun 2021 Preclinical trials in Osteoarthritis in South Korea (unspecified route), before June 2021